Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo

Acta Oto-Laryngologica

Volumn 123, Issue 5, 2003, Pages 588-593

  Albera, Roberto ^a   Ciuffolotti, Roberto ^b   Di Cicco, Maurizio ^c   De Benedittis, Giuseppe ^d   Grazioli, Irene ^e   Melzi, Gabriella ^e   Mira, Eugenio ^f   Pallestrini, Eugenio ^g   Passali, Desiderio ^h   Serra, Agostino ⁱ   Vicini, Claudio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e Solvay Pharma SpA   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ UNIVERSITY OF CATANIA   (Italy)

Author keywords

Betahistine; Dizziness Handicap Inventory; Flunarizine; Vestibular vertigo

Indexed keywords

BETAHISTINE; FLUNARIZINE; PLACEBO; VERTISERC;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; EMOTION; FEMALE; FITNESS; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECURRENT DISEASE; SCORING SYSTEM; SELF EVALUATION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO; VESTIBULAR SYSTEM;

ADULT; AGED; BETAHISTINE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUNARIZINE; HISTAMINE AGONISTS; HUMANS; MALE; MENIERE'S DISEASE; MIDDLE AGED; QUESTIONNAIRES; RECURRENCE; TREATMENT OUTCOME; VASODILATOR AGENTS; VERTIGO;

EID: 0038574710     PISSN: 00016489     EISSN: None     Source Type: Journal    
DOI: 10.1080/00016480310001475     Document Type: Article

References (25)

1. Honrubia V, Bell TS, Harris MR, Baloh RW, Fisher LM. Quantitative evaluation of dizziness characteristics and impact on quality of life. Am J Otol 1996; 17: 595-602.
2. Jacobson GP, Newman CW. The development of the Dizziness Handicap Inventory. Arch Otolaryngol Head Neck Surg 1990; 116: 424-7.
3. Dziadziola JK, Laurikainen EL, Rachel JD, Quirk WS. Betahistine increases vestibular blood flow. Otolaryngol Head Neck Surg 1999; 120: 400-5.
4. Arrang JM, Garbarg M, Quach TT, Dam Trung Tuong M, Yeramian E, Schwartz JC. Actions of betahistine at histamine receptors in the brain. Eur J Pharmacol 1985; 111: 73-84.
5. Botta L, Mira E, Valli S, Perin P, Zucca G, Valli P. Effects of betahistine on vestibular receptors of the frog. Acta Otolaryngol (Stockh) 1998; 118: 519-23.
6. Botta L, Mira E, Valli S, et al. Effects of betahistine metabolites on frog ampullar receptors. Acta Otolaryngol 2000; 120: 25-7.
7. Frew IJC, Menon GN. Betahistine hydrochloride in Ménière's disease. Postgrad Med J 1976; 52: 501-3.
8. Wilmot TJ, Menon GN. Betahistine in Ménière's disease. J Laryngol Otol 1976; 90: 833-40.
9. Claes J, Van de Heyning PH. A review of medical treatment for Meniere's disease. Acta Otolaryngol Suppl 2000; 544: 34-9.
10. Oosterveld WJ. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo controlled study. J Laryngol Otol 1984; 98: 37-41.
11. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine. A review of its pharmacodynamic and phamacokinetic properties and therapeutic use. Drugs 1984; 27: 6-44.
12. Haid T. Evaluation of flunarizine in patients with Meniere's disease. Subjective and vestibular findings. Acta Otolaryngol (Stockh) 1988; 460: 149-53.
13. Elbaz P. Flunarizine and betahistine. Two different therapeutic approaches in vertigo compared in a double-blind study. Acta Otolaryngol (Stockh) 1988; 460: 143-8.
14. Fraysse B, Bebear JP, Dubreuil C, Berges C, Dauman R. Betahistine dihydrochloride versus flunarizine. A double-blind study on recurrent vertigo with or without cochlear syndrome typical of Ménière's disease. Acta Otolaryngol Suppl (Stockh) 1991; 490: 1-10.
15. Gioffrè P. I questionari anamnestici. In: Guidetti G, ed. Diagnosi e terapia dei disturbi dell. equilibrio'. Rome: Editore Marrapese, 1996: 191-203.
16. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Ménière's disease. Otolaryngol Head Neck Surg 1995; 113: 181-5.
17. Laurikainen EL, Miller JF, Pyykko I. Betahistine effects on cochlear blood flow: from the laboratory to the clinic. Acta Otolaryngol Suppl 2000; 544: 5-7.
18. Valli P. Betahistine reduces the resting firing rate of vestibular receptors in the frog. Acta Otolaryngol Suppl 2000; 544: 8-10.
19. Costantinescu L, Schneider D, Claussen CF. The influence of betahistine on the vestibular evoked potentials in patients with peripheral vestibular disorders. 3rd European Congress EUFOS, Budapest, Hungary, 9-14 June, 1996: 95.
20. Kingma H, Bonink M, Meulenbroeks A, Konijnenberg H. Dose-dependent effect of betahistine on the vestibular-ocular reflex: a double-blind, placebo controlled study in patients with paroxysmal vertigo. Acta Otolaryngol (Stockh) 1997; 117: 641-6.
21. Perez N, Espinosa JM, Fernandez S, Garcia-Tapia R. Use of distortion-product otoacoustic emissions for auditory evaluation in Meniere's disease. Eur Arch Otorhinolaryngol 1997; 254: 329-42.
22. Tighilet B, Lacour M. Histamine immunoreactivity changes in vestibular-lesioned and histaminergic-treated cats. Eur J Pharmacol 1997; 330: 65-77.
23. Lacour M, Tighilet B. Vestibular compensation in the cat: the role of the histaminergic system. Acta Otolaryngol Suppl 2000; 544: 15-8.
24. Dutia MB. Betahistine, vestibular function and compensation: in vitro studies of vestibular function and plasticity. Acta Otolaryngol Suppl 2000; 544: 11-4.
25. Colletti V. Medical treatment in Meniere's disease: avoiding vestibular neurectomy and facilitating postoperative compensation. Acta Otolaryngol Suppl 2000; 544: 27-33.